Clinical Trial

xDRIVE for Florida-based Cancer Patients

Recruiting
View on ClinicalTrials.gov →
Summary
Through this study funded by the Florida Cancer Innovation Fund, First Ascent will demonstrate state-wide feasibility of providing xDRIVE Functional Precision Medicine + Artificial Intelligence platform by assessing patient clinical benefit and health economics impacts. As this is a feasibility study, results will be returned to the physician and the physician may use the data to inform the next line of treatment. The investigator will run a prospective single-arm feasibility study providing the xDRIVE FPM AI platform to n = 210+ cancer patients throughout the state of Florida, especially those from underserved populations (pediatric patients and patients in Black, Brown, Hispanic, and rural communities).
Protocol Amendment History 3 amendments
This ClinicalTrials.gov record has been amended 3 times since 2025-09-03; most recent amendment 2026-05-17.
Status change: Not Yet Recruiting → Recruiting 2025-11-05
Trial Details
NCT Number NCT07167381
Lead Sponsor First Ascent Biomedical Inc.
Collaborators: Florida International University
Conditions Cancer, Neoplams, Refractory, Recurrence, Leukaemia, Lymphoma, Solid Tumor Malignancies, Solid Cancers
Enrollment 210 participants
Start Date 2025-11-01
Primary Completion 2026-11-01 (estimated)
Study Completion 2027-04-01 (estimated)
Updated on ClinicalTrials.gov 2026-05-19